+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma



The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma



Nuclear Medicine Communications 37(1): 43-49



The aim of this study was to investigate the relationship between volume-based quantitative PET parameters and survival in patients with malignant pleural mesothelioma (MPM) and to evaluate the potential value of bone marrow (BM) uptake in predicting prognosis. We retrospectively reviewed the data of 51 patients with MPM who underwent initial staging by fluorine-18-fluorodeoxyglucose (F-FDG) PET/computerized tomography (PET/CT). F-FDG-PET images were visually and quantitatively re-evaluated and maximum standardized uptake values (SUVmax), mean standardized uptake values (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis of primary tumors, and pleural thickening were calculated. In addition, BM and liver uptakes were measured; also, the degree of BM uptake was scored visually. BM/liver ratio and visual BM uptake score were noted. The correlations between quantitative PET parameters, BM uptake, and overall survival were analyzed. F-FDG-PET scans upstaged 6 (11.8%) of 51 patients because of detection of previously unknown distant metastasis. On univariate analysis, advanced disease stage, high leukocyte count (≥10×10/ml), pleural thickening greater than 13 mm, SUVmax, SUVmean, MTV, total lesion glycolysis, BM/liver greater than 1.01, and visual score 1 and 2 were negative prognostic factors (P<0.05). In multivariate analysis, SUVmax greater than 8.6 [P=0.027, hazard ratio (HR): 2.961], MTV greater than 112 (P=0.001, HR: 4.861), and visual score 2 (P=0.035, HR: 3.827) were associated independently with a poor prognosis. The presence of distant metastasis is more predictive of survival than PET nodal status in MPM patients. PET/CT has the potential to provide prognostic information in MPM patients and there was a good correlation between overall survival and volume-based PET parameters. Determination of BM uptake may contribute toward the prediction of patient outcome with other quantitative PET parameters.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 059094071

Download citation: RISBibTeXText

PMID: 26440572


Related references

Prognostic value of pretreatment volume-based quantitative 18 F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. European Journal of Radiology 86: 176-183, 2017

Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. Journal of Nuclear Medicine 48(9): 1449-1458, 2007

Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery. Journal of Thoracic Oncology 14(2): 288-293, 2019

A Comparison of Dosimetric Parameters in PET-Based Active Bone Marrow Volume and Total Bone Volume in Prediction of Hematologic Toxicity in Cervical Cancer Patients Treated with Chemoradiation. International Journal of Radiation Oncology*biology*physics 96(2): E307-E308, 2016

Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Annals of Surgical Oncology 17(10): 2787-2794, 2010

Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 25(36): 5770-5776, 2007

Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. Journal of Thoracic Oncology 7(7): 1184-1191, 2012

Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988-2000: a population-based study. European Journal of Cancer Prevention 14(3): 195-199, 2005

The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. European Journal of Nuclear Medicine and Molecular Imaging 41(2): 276-282, 2014

Malignant Pleural Mesothelioma with Bone Marrow Metastases. Internal Medicine 57(17): 2541-2545, 2018

Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. Radiology and Oncology 46(2): 136-144, 2012

Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. European Journal of Cardio-Thoracic Surgery 49(6): 1642-1647, 2016

Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. Ajr. American Journal of Roentgenology 198(2): 359-363, 2012

Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. Medical Oncology 31(8): 74, 2014

Malignant pleural mesothelioma: a population-based study of survival. Journal of Thoracic Oncology 5(11): 1841-1848, 2010